<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">HJO</journal-id><journal-title-group><journal-title>Hans Journal of Ophthalmology</journal-title></journal-title-group><issn pub-type="epub">2167-6542</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/HJO.2018.71001</article-id><article-id pub-id-type="publisher-id">HJO-23968</article-id><article-categories><subj-group subj-group-type="heading"><subject>HJO20180100000_30918560.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  康柏西普治疗视网膜分支静脉阻塞伴黄斑水肿的短期疗效观察
  Short-Term Therapeutic Effects of Intravitreal Conbercept Injection for Macular Edema Secondary to Branch Retinal Vein Occlusion
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>赵</surname><given-names>芃芃</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>秦</surname><given-names>梅</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib></contrib-group><aff id="aff1"><addr-line>蚌埠医学院第一附属医院眼科，安徽 蚌埠</addr-line></aff><author-notes><corresp id="cor1">* E-mail:<email>919857971@qq.com(赵芃)</email>;<email>bbmcqm@163.com(秦梅)</email>;</corresp></author-notes><pub-date pub-type="epub"><day>07</day><month>03</month><year>2018</year></pub-date><volume>07</volume><issue>01</issue><fpage>1</fpage><lpage>6</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
   
   目的：观察玻璃体腔内注射康柏西普治疗视网膜分支静脉阻塞合并黄斑水肿的短期临床疗效。方法：收集我院就诊诊断为BRVO伴有ME的患者14例，共计14只眼，采用“2 + PRN”治疗方案行玻璃体腔内注射康柏西普0.5 mg/0.05 mL，随诊3个月观察患者注药前后最佳矫正视力(BCVA)、黄斑中心厚度(CMT)的变化，同时观察患者眼压及并发症的出现。结果：14例(14眼) BRVO并发ME患者于随访末期有12例获得0.4 (LogMAR)及以下的最佳矫正视力，治疗前、随诊1周、1个月、3个月平均BCVA分别为0.70 &#177; 0.35、0.56 &#177; 0.35、0.45 &#177; 0.29、0.32 &#177; 0.23；术后1月与3月BCVA与术前相比较提高，差异有统计学意义(p &lt; 0.05)。14例患者治疗前、随诊1周、1个月、3个月平均CMT分别为(454.57 &#177; 143.53) μm、(329.57 &#177; 92.53) μm、(281.00 &#177; 61.00) μm、(249.43 &#177; 65.17) μm，术后各随诊时间平均CMT较术前均降低，差异具有统计学意义(p &lt; 0.05)。随诊各时间患者眼压均在正常范围内，与注药前比较差异不具有统计学意义(p &gt; 0.05)。结论：玻璃体腔内注射康柏西普治疗视网膜分支静脉阻塞合并黄斑水肿短期内能改善视力和促进黄斑水肿的消退，安全有效。 Objective: To assess the short-term clinical effects of intravitreal injection of conbercept for macular edema (ME) secondary to branch retinal vein occlusion (BRVO). Methods: A total of 14 patients (14 eyes) with macular edema following BRVO treated with “2 + PRN” intravitreal injection of conbercept 0.05 mg/0.05 mL were collected. The best corrected visual acuity (BCVA) and central macular thickness (CMT) were observed before treatment and 1 week, 1 month, 2 months, 3 months after treatment. Then, the changes in pre-treatment and post-treatment were compared, and the related complications were recorded. Results: Twelve of the 14 patients (14 eyes) compli-cated with ME achieved a BCVA of 0.4 (LogMAR) at the end of follow-up. The average BCVA of pre-treatment and 1 week, 1 months, 3 months follow-up were 0.70 &#177; 0.35, 0.56 &#177; 0.35, 0.45 &#177; 0.29 and 0.32 &#177; 0.23, respectively. The BCVA at 1 month and 3 months follow-up after operation was significantly higher than preoperative. The difference was statistically significant (p &lt; 0.05). The average CMT of the 14 patients were (454.57 &#177; 143.53) μm, (329.57 &#177; 92.53) μm, (281.00 &#177; 61.00) μm and (249.43 &#177; 65.17) μm respectively at before treatment, 1 week, 1 month and 3 months fol-low-up. The average CMT of each follow-up time after operation was lower than that before opera-tion, the difference was statistically significant (p &lt; 0.05). Intraocular pressure in patients with follow-up was within the normal range, compared with the injection before the difference was not statistically significant (p &gt; 0.05). Conclusion: Intravitreal injection of conbercept in the treatment of BRVO with ME can improve visual acuity and promote the regression of macular edema in a short-time and is safe and effective. 
  
 
</p></abstract><kwd-group><kwd>视网膜分支静脉阻塞，黄斑水肿，康柏西普, Branch Retinal Vein Occlusion</kwd><kwd> Macular Edema</kwd><kwd>Conbercept</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>康柏西普治疗视网膜分支静脉阻塞伴黄斑水肿的短期疗效观察<sup> </sup></title><p>赵芃芃，秦梅</p><p>蚌埠医学院第一附属医院眼科，安徽 蚌埠</p><p>收稿日期：2018年2月12日；录用日期：2018年2月28日；发布日期：2018年3月7日</p><disp-formula id="hanspub.23968-formula8"><graphic xlink:href="//html.hanspub.org/file/1-2230176x5_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>目的：观察玻璃体腔内注射康柏西普治疗视网膜分支静脉阻塞合并黄斑水肿的短期临床疗效。方法：收集我院就诊诊断为BRVO伴有ME的患者14例，共计14只眼，采用“2 + PRN”治疗方案行玻璃体腔内注射康柏西普0.5 mg/0.05 mL，随诊3个月观察患者注药前后最佳矫正视力(BCVA)、黄斑中心厚度(CMT)的变化，同时观察患者眼压及并发症的出现。结果：14例(14眼) BRVO并发ME患者于随访末期有12例获得0.4 (LogMAR)及以下的最佳矫正视力，治疗前、随诊1周、1个月、3个月平均BCVA分别为0.70 &#177; 0.35、0.56 &#177; 0.35、0.45 &#177; 0.29、0.32 &#177; 0.23；术后1月与3月BCVA与术前相比较提高，差异有统计学意义(p &lt; 0.05)。14例患者治疗前、随诊1周、1个月、3个月平均CMT分别为(454.57 &#177; 143.53) μm、(329.57 &#177; 92.53) μm、(281.00 &#177; 61.00) μm、(249.43 &#177; 65.17) μm，术后各随诊时间平均CMT较术前均降低，差异具有统计学意义(p &lt; 0.05)。随诊各时间患者眼压均在正常范围内，与注药前比较差异不具有统计学意义(p &gt; 0.05)。结论：玻璃体腔内注射康柏西普治疗视网膜分支静脉阻塞合并黄斑水肿短期内能改善视力和促进黄斑水肿的消退，安全有效。</p><p>关键词 :视网膜分支静脉阻塞，黄斑水肿，康柏西普</p><disp-formula id="hanspub.23968-formula9"><graphic xlink:href="//html.hanspub.org/file/1-2230176x6_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2018 by authors and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/1-2230176x7_hanspub.png" /> <img src="//html.hanspub.org/file/1-2230176x8_hanspub.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>视网膜静脉阻塞(retinal vein occlusion, RVO)是我国仅次于糖尿病性视网膜病变的第二大视网膜血管类疾病，可被分为视网膜中央静脉阻塞(central retinal vein occlusion, CRVO)和视网膜分支静脉阻塞(branch retinal vein occlusion, BRVO)，其中BRVO占4/5，因其易并发黄斑水肿(macular edema, ME)，可对视功能造成严重损害 [<xref ref-type="bibr" rid="hanspub.23968-ref1">1</xref>] 。传统治疗方法主要包括曲安奈德玻璃体腔内注射和黄斑区格栅样光凝。曲安奈德为糖皮质激素，长期应用后会引起白内障、青光眼等严重并发症，近年来对于抗血管内皮生长因子(vascular endothelial growth factor, VEGF)药物的研究较多，目前已有大量研究证实抗VEGF药物治疗BRVO合并ME安全有效 [<xref ref-type="bibr" rid="hanspub.23968-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.23968-ref3">3</xref>] ，相较于曲安奈德更为安全 [<xref ref-type="bibr" rid="hanspub.23968-ref4">4</xref>] ，因此，曲安奈德在临床上应用已越来越少。黄斑区格栅样光凝治疗BRVO能够稳定视力，但会对视网膜造成创伤，存在加重黄斑水肿的可能，对初诊视力较差的患者视力提高有限 [<xref ref-type="bibr" rid="hanspub.23968-ref5">5</xref>] [<xref ref-type="bibr" rid="hanspub.23968-ref6">6</xref>] 。康柏西普是一种新型血管内皮生长因子受体，可与多种VEGF亚型及胎盘生长因子相结合并使其失活 [<xref ref-type="bibr" rid="hanspub.23968-ref7">7</xref>] 。本研究对14例BRVO合并ME患者采用玻璃体腔内注射康柏西普，并观察治疗前后CMT、BCVA、眼压等指标，以评价其治疗BRVO合并ME的短期临床疗效。</p></sec><sec id="s4"><title>2. 资料与方法</title><sec id="s4_1"><title>2.1. 一般资料</title><p>回顾性分析2016年10月至2017年9月在我院眼科确诊为BRVO合并ME的患者14例(14眼)，男9例(9眼)，女5例(5眼)，年龄35~71岁；病程4月内。所有患者均遵循自愿原则，经伦理委员会同意。</p><p>纳入标准：1) 经裂隙灯、眼底检查、OCT及眼底照相等检查确诊为BRVO，诊断标准：见受阻分支静脉迂曲扩张，局部受累区域视网膜表层出血、水肿，可有棉绒斑及伴随动脉变细；2) 病程4个月以内；3) 光学相干断层扫描(optical coherence tomography, OCT)提示黄斑中心凹厚度(central macular thickness, CMT) &gt; 250 μm；排除标准：1) 患有糖尿病、黄斑变性等其他影响黄斑水肿疾病；2) 患有白内障、青光眼、葡萄膜炎等影响患者视力及OCT检查者；3) 曾行玻璃体腔内抗VEGF药物、激素及激光治疗者；4) 存在严重角膜炎、结膜炎及泪道感染等可能引起术后眼内感染者。</p></sec><sec id="s4_2"><title>2.2. 方法</title><sec id="s4_2_1"><title>2.2.1. 术前检查</title><p>所有患者术前用国际标准视力表查最佳矫正视力(best correct visual acuity, BCVA)，以最小分辨角对数视力Log MAR形式记录；行裂隙灯、间接眼底镜、非接触式眼压计检查；OCT(日本Topcon-2000)检查黄斑区CMT及其形态。行内眼常规术前准备。</p></sec><sec id="s4_2_2"><title>2.2.2. 手术方法</title><p>稀释后的聚维酮碘浸泡结膜囊1分钟，生理盐水冲洗，奥布卡因点眼表面麻醉2次。专用冲洗针头抽取10 mg&#183;mL<sup>−1</sup>康柏西普(成都康弘生物有限公司) 0.05 mL，更换无菌针头，避开血管于角巩膜缘后4 mm处垂直穿刺注射，注射后，无菌棉签压迫1分钟，包眼。术后予以左氧氟沙星滴眼液、玻璃酸钠滴眼液、普拉洛芬滴眼液点术眼7 d。</p></sec><sec id="s4_2_3"><title>2.2.3. 随访观察</title><p>前两个月每个月注射一次，第二次注射后一周、1个月、2个月、3个月用与术前检查相同的仪器和方法进行检查眼前节、眼底、眼压、CMT、BCVA。复查时若发现视力下降1行视标及以上，同时CMT增加大于100 μm或视力高于0.4，且CMT ≥ 250 μm，行再次注射，每个患者重复注药时间间隔均 &gt; 30 d，药物及剂量同前。</p></sec></sec><sec id="s4_3"><title>2.3. 统计学方</title><p>采用SPSS16.0软件进行统计学分析。计量资料以 x &#175; &#177; s 表示，采用单因素方差分析，P &lt; 0.05为差异有统计学意义。</p></sec></sec><sec id="s5"><title>3. 结果</title><sec id="s5_1"><title>3.1. 视力及OCT观察指标</title><p>14例(14眼)BRVO患者随访时间三个月，末次随诊时所有患者ME均有不同程度消退，有10例(71.43%)患者CMT &lt; 250 μm，同时BCVA恢复到0.3及以下，所有患者术后一个月、三个月平均BCVA与注药前相比较均有明显提高，差异有统计学意义(p &lt; 0.05)；术后各随访时间点平均CMT与术前比较均降低，差异有统计学意义(p &lt; 0.05)，术后各时间点眼压与术前相比无统计学差异(p &gt; 0.05)，详见表1。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Each indicator changes in 3 months follow-u</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >观察阶段</th><th align="center" valign="middle" >BCVA</th><th align="center" valign="middle" >CMT(μm)</th><th align="center" valign="middle" >NCT(mmHg)</th></tr></thead><tr><td align="center" valign="middle" >注药前</td><td align="center" valign="middle" >0.70 &#177; 0.35</td><td align="center" valign="middle" >454.57 &#177; 143.53</td><td align="center" valign="middle" >16.08 &#177; 0.79</td></tr><tr><td align="center" valign="middle" >注药后1周</td><td align="center" valign="middle" >0.56 &#177; 0.35</td><td align="center" valign="middle" >329.57 &#177; 92.53<sup>△</sup></td><td align="center" valign="middle" >15.99 &#177; 1.06</td></tr><tr><td align="center" valign="middle" >注药后1个月</td><td align="center" valign="middle" >0.45 &#177; 0.29<sup>*</sup></td><td align="center" valign="middle" >281.00 &#177; 61.00<sup>△</sup></td><td align="center" valign="middle" >15.78 &#177; 1.16</td></tr><tr><td align="center" valign="middle" >注药后3个月</td><td align="center" valign="middle" >0.32 &#177; 0.23<sup>△</sup></td><td align="center" valign="middle" >249.43 &#177; 65.17<sup>△</sup></td><td align="center" valign="middle" >15.95 &#177; 1.05</td></tr></tbody></table></table-wrap><p>表1. 随诊3个月各指标均值的变化情况</p><p>注：与注药前比较<sup>△</sup>p &lt; 0.01，<sup>*</sup>p &lt; 0.05。</p></sec><sec id="s5_2"><title>3.2. 并发症</title><p>随访期间2例患者术后注射部位轻度球结膜下出血，于注药后一周内自行消退；1例患者于注药后第一天出现流泪及异物感不适，为角膜上皮粗糙，予以玻璃酸钠应用，第二天恢复正常；所有患眼均未出现眼压升高、眼内炎、视网膜脱离、玻璃体积血等严重并发症。</p></sec></sec><sec id="s6"><title>4. 讨论</title><p>BRVO的发病机制目前尚不明确，可能与动脉硬化及血液流变学异常有关。有研究指出 [<xref ref-type="bibr" rid="hanspub.23968-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.23968-ref9">9</xref>] ，当视网膜动脉发生硬化时，动静脉交叉处动脉对静脉造成机械压迫，局部血液流速减慢及血液粘滞度增高，血管内皮、内界膜发生损害，引发静脉阻塞。进而血管内皮细胞凋亡，血管通透性增高，对组织缺氧的耐受性降低，视网膜发生水肿及无灌注区形成。</p><p>阻塞的静脉血管内皮细胞可以释放VEGF，造成血–视网膜屏障破坏，形成ME [<xref ref-type="bibr" rid="hanspub.23968-ref10">10</xref>] ，是造成BRVO视力损害的主要原因。据统计，30%BRVO患眼会发生ME [<xref ref-type="bibr" rid="hanspub.23968-ref11">11</xref>] 。血管内皮生长因子(VEGF)、胎盘生长因子、血小板源生长因子及部分炎症因子参与ME的发生发展，VEGF是其中最重要的调控因子 [<xref ref-type="bibr" rid="hanspub.23968-ref12">12</xref>] [<xref ref-type="bibr" rid="hanspub.23968-ref13">13</xref>] 。有研究指出，BRVO患者玻璃体腔及房水中VEGF水平较正常人明显升高，与ME的程度呈正相关，与患者的视力呈负相关 [<xref ref-type="bibr" rid="hanspub.23968-ref14">14</xref>] [<xref ref-type="bibr" rid="hanspub.23968-ref15">15</xref>] 。缺血、缺氧、视网膜无灌注均会促进VEGF的表达，加重ME [<xref ref-type="bibr" rid="hanspub.23968-ref16">16</xref>] 。长期的ME造成黄斑区结构改变，引起视功能的永久性损害。</p><p>目前抗VEGF药物有以雷珠单抗(lucentis)为代表的单抗类和阿柏西普(aflibercept)为代表的融合蛋白两大类。我国应用的融合蛋白类药物为康柏西普(conbercept)，是我国自主研发，利用仓鼠卵巢细胞生产的新型抗VEGF融合蛋白，其作用途径广，可与VEGF-A、VEGF-B及胎盘生长因子结合，且较单抗类药物及内源性VEGF受体对VEGF-A有更强的亲和力，具有非常强的抗新生血管作用 [<xref ref-type="bibr" rid="hanspub.23968-ref17">17</xref>] 。</p><p>本研究对14例BRVO合并ME患者进行玻璃体腔内康柏西普注射治疗，采取“2 + PRN”康柏西普玻璃体腔内注射治疗方案，每月随访，第二次注射后随访3个月，再次注射的指征为随诊时视力下降1行视标及以上，同时CMT增加大于100 μm；或视力高于0.4，且CMT ≥ 250 μm。在接受治疗后各随访时间点患者CMT较治疗前均有明显下降，差异具有统计学意义(p &lt; 0.05)；注药后1个月及3个月BCVA较注药前明显提高，差异具有统计学意义(p &lt; 0.05)，视力恢复与CMT下降程度呈正相关。表明BRVO合并ME患者行玻璃体腔内康柏西普注射治疗后短期内患者视力及黄斑解剖形态均有显著改善，与国内现有研究结果一致 [<xref ref-type="bibr" rid="hanspub.23968-ref18">18</xref>] [<xref ref-type="bibr" rid="hanspub.23968-ref19">19</xref>] 。14例患者中，末次随访时有10例患者黄斑区形态基本恢复正常，该10例患者视力均恢复至0.3及以下；余下4例仍有不同程度水肿，其中3例黄斑区水肿较轻，黄斑中心凹结构存在，各层结构反光连续，视力达0.4；另外1例视力1.0，与初诊相比较视力改善不明显，该患者反复注药后虽然CMT较治疗前明显降低，但是仍然存在持续的黄斑水肿，黄斑中心凹正常结构不见，可能与视网膜无灌注区存在，VEGF水平反复升高有关，单纯抗VEGF药物治疗可能不够，需要联合视网膜激光治疗。另外，该患者于注药前即有较为严重的黄斑水肿，且水肿波及黄斑椭圆体区，注药后黄斑区总厚度虽降低，但是椭圆体区的水肿仍然存在，且外界膜和光感受器内外节交接处有不同程度的连续性中断。近年来国内外有研究发现BRVO患者初诊视力与黄斑区视网膜厚度呈负相关，但预后视力与该厚度并无相关性，而与中心凹外核层及椭圆体区厚度相关 [<xref ref-type="bibr" rid="hanspub.23968-ref20">20</xref>] [<xref ref-type="bibr" rid="hanspub.23968-ref21">21</xref>] 。提示存在椭圆体区光感受器细胞损害者可能预后较差。</p><p>本研究中，14例患者随访期间均未出现全身不良反应，局部并发症轻微，例如结膜充血，结膜下出血，均在较短时间内恢复，无眼压增高及眼内感染等并发症出现，提示康柏西普玻璃体腔内注射短期内安全性较高。但是本研究样本量较少，随访时间短，对于长期疗效及安全性还需进一步研究证实。</p><p>综上所述，康柏西普玻璃体腔内注射治疗BRVO并发ME短期内安全有效，但需重复注射，其远期疗效及安全性还有待进一步研究。</p></sec><sec id="s7"><title>文章引用</title><p>赵芃芃,秦 梅. 康柏西普治疗视网膜分支静脉阻塞伴黄斑水肿的短期疗效观察Short-Term Therapeutic Effects of Intravitreal Conbercept Injection for Macular Edema Secondary to Branch Retinal Vein Occlusion[J]. 眼科学, 2018, 07(01): 1-6. http://dx.doi.org/10.12677/HJO.2018.71001</p></sec><sec id="s8"><title>参考文献 (References)</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.23968-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Rogers, S., Mcintosh, R.L., Cheung, N., et al. (2010) The Prevalence of Retinal Vein Occlusion: Pooled Data from Population Studies from the United States, Europe, Asia, and Australia. Ophthalmology, 117, 313-9 e1.</mixed-citation></ref><ref id="hanspub.23968-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Brown, D.M., Campochiaro, P.A., Bhisitkul, R.B., et al. (2011) Sustained Benefits from Ranibizumab for Macular Edema Following Branch Retinal Vein Occlusion: 12-Month Outcomes of a Phase III Study. Ophthalmology, 118, 1594-1602. https://doi.org/10.1016/j.ophtha.2011.02.022</mixed-citation></ref><ref id="hanspub.23968-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Clark, W.L., Boyer, D.S., Heier, J.S., et al. (2016) Intravitreal Aflibercept for Macular Edema Following Branch Retinal Vein Occlusion: 52-Week Results of the VIBRANT Study. Ophthalmology, 123, 330-336.  
https://doi.org/10.1016/j.ophtha.2015.09.035</mixed-citation></ref><ref id="hanspub.23968-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Tan, M.H., Mcallister, I.L., Gillies, M.E., et al. (2014) Randomized Controlled Trial of Intravitreal Ranibizumab versus Standard Grid Laser for Macular Edema Following Branch Retinal Vein Occlusion. American Journal of Ophthalmology, 157, 237-247 e1.</mixed-citation></ref><ref id="hanspub.23968-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">白石. 不同方法治疗视网膜分支静脉阻塞继发黄斑水肿的疗效[J]. 国际眼科杂志, 2017, 17(4): 648-651.</mixed-citation></ref><ref id="hanspub.23968-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Arnarsson, A. and Stefansson, E. (2000) Laser Treatment and the Mechanism of Edema Reduction in Branch Retinal Vein Occlusion. Investigative Ophthalmology &amp; Visual Science, 41, 877-879.</mixed-citation></ref><ref id="hanspub.23968-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Wang, Q., Li, T., Wu, Z., et al. (2013) Novel VEGF Decoy Receptor Fusion Protein Conbercept Targeting Multiple VEGF Isoforms Provide Remarkable Anti-Angiogenesis Effect in Vivo. PLoS One, 8, e70544.  
https://doi.org/10.1371/journal.pone.0070544</mixed-citation></ref><ref id="hanspub.23968-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Dominguez, E., Raoul, W., Calippe, B., et al. (2015) Experimental Branch Retinal Vein Occlusion Induces Upstream Pericyte Loss and Vascular Destabilization. PLoS One, 10, e0132644. https://doi.org/10.1371/journal.pone.0132644</mixed-citation></ref><ref id="hanspub.23968-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Christoffersen, N.L. and Larsen, M. (1999) Pathophysiology and Hemody-namics of Branch Retinal Vein Occlusion. Ophthalmology, 106, 2054-2062. https://doi.org/10.1016/S0161-6420(99)90483-9</mixed-citation></ref><ref id="hanspub.23968-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Karia, N. (2010) Retinal Vein Occlusion: Pathophysiology and Treatment Options. Clinical Ophthalmology, 4, 809-816.  
https://doi.org/10.2147/OPTH.S7631</mixed-citation></ref><ref id="hanspub.23968-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Yau, J.W., Lee, P., Wong, T.Y., et al. (2008) Retinal Vein Occlusion: An Approach to Diagnosis, Systemic Risk Factors and Management. Internal Medicine Journal, 38, 904-910. https://doi.org/10.1111/j.1445-5994.2008.01720.x</mixed-citation></ref><ref id="hanspub.23968-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Ehlers, J.P. and Fekrat, S. (2011) Retinal Vein Occlusion: Beyond the Acute Event. Survey of Ophthalmology, 56, 281-299. https://doi.org/10.1016/j.survophthal.2010.11.006</mixed-citation></ref><ref id="hanspub.23968-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Noma, H., Funatsu, H., Mimura, T., et al. (2009) Vitreous Levels of Interleukin-6 and Vascular Endothelial Growth Factor in Macular Edema with Central Retinal Vein Occlusion. Ophthalmology, 116, 87-93.  
https://doi.org/10.1016/j.ophtha.2008.09.034</mixed-citation></ref><ref id="hanspub.23968-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Bhisitkul, R.B., Campochiaro, P.A., Shapiro, H., et al. (2013) Predictive Value in Retinal Vein Occlusions of Early versus Late or Incomplete Ranibizumab Response Defined by Optical Coherence Tomography. Ophthalmology, 120, 1057-1063. https://doi.org/10.1016/j.ophtha.2012.11.011</mixed-citation></ref><ref id="hanspub.23968-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Wroblewski, J.J., Wells 3rd, J.A. and Gonzales, C.R. (2010) Pegaptanib Sodium for Macular Edema Secondary to Branch Retinal Vein Occlusion. American Journal of Ophthalmology, 149, 147-154.  
https://doi.org/10.1016/j.ajo.2009.08.005</mixed-citation></ref><ref id="hanspub.23968-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Jaulim, A., Ahmed, B., Khanam, T., et al. (2013) Branch Retinal Vein Occlusion: Epidemiology, Pathogenesis, Risk Factors, Clinical Features, Diagnosis, and Complications. An Update of the Literature. Retina, 33, 901-910.  
https://doi.org/10.1097/IAE.0b013e3182870c15</mixed-citation></ref><ref id="hanspub.23968-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, M., Zhang, J., Yan, M. and Yu, D.C. (2008) Recombinant An-ti-Vascular Endothelial Growth Factor Fusion Protein Efficiently Suppresses Choridal Neovasularization in Monkeys. Molecular Vision, 14, 37-49.</mixed-citation></ref><ref id="hanspub.23968-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">宋莉, 沙翔垠, 郑瑜, 等. 康柏西普治疗视网膜分支静脉阻塞继发黄斑水肿疗效分析[J]. 广东医学, 2017, 38(5): 778-780.</mixed-citation></ref><ref id="hanspub.23968-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">邢凯, 亢泽峰. 玻璃体腔内注射康柏西普治疗视网膜分支静脉阻塞继发黄斑水肿的疗效分析[J]. 山东大学耳鼻喉眼学报, 2016(1): 80-82.</mixed-citation></ref><ref id="hanspub.23968-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Noma, H., Funatsu, H., Harino, S., et al. (2010) Influence of Macular Microcirculation and Retinal Thickness on Visual Acuity in Patients with Branch Retinal Vein Occlusion and Macular Edema. Japanese Journal of Ophthalmology, 54, 430-434. https://doi.org/10.1007/s10384-010-0834-9</mixed-citation></ref><ref id="hanspub.23968-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Altunel, O., Duru, N., Goktas, A., et al. (2017) Evaluation of Foveal Photoreceptor Layer in Eyes with Macular Edema Associated with Branch Retinal Vein Occlusion after Ozurdex Treatment. International Ophthalmology, 37, 333-339.  
https://doi.org/10.1007/s10792-016-0261-0</mixed-citation></ref></ref-list></back></article>